General guidelines are presented on the types of patent protection available for inventions arising from research in the field of monoclonal antibodies, using concepts drawn from European case law and expert practice.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
European Patent Office. European Patent Convention, 15th edn (European Patent Office, 2013).
Ballester Rodé s, A. et al. (eds) Case Law of the Boards of Appeal of the European Patent Office 8th edn, 275–278 (European Patent Office, 2016).
Eli Lilly & Co. v. Human Genome Sciences Inc., C-493/12 (2013).
European Patent Office. Guidelines for Examination in the European Patent Office 747–749 (European Patent Office, 2017).
Art. 53(c) EPC.
Arts. 54(4) and 54(5) EPC.
EPO Board of Appeal decisions: T499/88 (EP59598: Immunoglobulins/Unilever), T36/90 (EP 676642: Tumor cells/Bogoch), T906/91 (EP 198179: Monoclonal antibody to theophylline/DuPont).
EP 0865448 (12 June 1997).
EPO Board of Appeal rulings: T355/92 (EP 193880: anti-FSH antibody (Boehringer Mannheim), T510/94 (EP 125722: Monoclonal antibody OKT5/ORTHO).
Ballester Rodés, A. et al. (eds) Case Law of the Boards of Appeal of the European Patent Office 8th edn. 201–203 (European Patent Office, 2016).
EPO Board of Appeal decision T1212/97 (EP1125023: Immunoglobulin preparation/Genentech).
Art. 83 EPC.
European Patent Office. Guidelines for Examination in the European Patent Office 689–691 (European Patent Office, 2012).
Art. 56 EPC.
The authors declare no competing financial interests.
About this article
Cite this article
Germinario, C., Bertoli, S., Rampinelli, P. et al. Patentability of antibodies for therapeutic use in Europe. Nat Biotechnol 36, 402–405 (2018). https://doi.org/10.1038/nbt.4134